UBS Maintains a 'Neutral' on Luminex (LMNX); Raising Guidance on Good '12 Start

May 1, 2012 12:39 PM EDT
Get Alerts LMNX Hot Sheet
Price: $8.92 -1.44%

Rating Summary:
    1 Buy, 9 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
UBS maintains a 'Neutral' on Luminex (NASDAQ: LMNX) price target raised from $22 to $25.

Analyst, Daniel Arias, said, "Q1 saw strong assay growth (+80%y/y; +5% q/q) on EraGen product uptake & cont’d growth from CF assays, which offset soft RVP sales. LMNX placed 206 systems as MAGPIX continues to penetrate the research setting, but instrument sales fell 9%, while consumables were down 21% on bulk order lumpiness from one partner...We now project 2012-13 sales of $211M (+15% y/y; up from $208M) & $241M, respectively, with EPS of $0.44 (was $0.41) & $0.69 (up from $0.66)."

UBS raises FY12 EPS estimate from $0.41 to $0.44, and FY13 from $0.66 to $0.69. FY12/13 revs increased to $211M/$241M.


For an analyst ratings summary and ratings history on Luminex click here. For more ratings news on Luminex click here.

Shares of Luminex closed at $25.04 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS